Vrije Universiteit Brussels Boosts Nanobody Research with MILabs Platform

Press release: Vrije Universiteit Brussels installs MILabs new PET-SPECT-CT-MRI platform for nanobody research

UTRECHT, THE NETHERLANDS, March 10th, 2015

Today MILabs announces the installation of its new PET-SPECT-CT-MR preclinical imaging platform at the In Vivo Cellular and Molecular Imaging (ICMI) lab at the Vrije University Brussels (VUB) Belgium.

The highly comprehensive imaging platform combines the best PET-SPECT functional imaging capabilities (sub-half-mm SPECT resolution and sub-mm  PET resolution) with high resolution anatomical imaging from an integrated  X-ray CT subsystem and/or a compact cryogen free 1.5 T MRI unit. The new PET-SPECT-CT-MRI platform will significantly expand the imaging capabilities at the VUB In vivo Cellular and Molecular Imaging Lab.

“With this unique PET-SPECT-CT-MR platform we can perform high throughput and validated imaging pharmacokinetics in specific organs as well as the whole body in vivo, very fast and with extreme high accuracy” says Prof. Tony Lahoute, principal investigator at ICMI lab and head of Nuclear Medicine of the university hospital of the Vrije University Brussel. His groundbreaking nanobody research program has resulted already in several compounds for molecular imaging and therapy in disease areas such as oncology, immunology, cardiology and diabetes. The preclinical imaging research at ICMI has been the basis for several clinical trial programs using radiolabeled nanobodies.
“The newly acquired infrastructure will also be used to implement new ideas on image quality and quantitative accuracy of different radiotracers particularly with the unique capabilities for simultaneously measuring multiple tracers across the entire nuclear energy spectrum” continues Prof. Michel Defrise, principal investigator of the ICMI lab.

“The continues efforts by the Flemish government and the Hercules foundation to provide support to research groups and core facilities such as the ICMI lab, enables MILabs to collaborate on innovating her imaging protocols and contributes in this way to the development of new therapies for major diseases” adds Freek Beekman, Ph.D., CEO and founder of MILabs BV.

About the In Vivo Cellular and Molecular Imaging Lab 

At the In Vivo Cellular and Molecular Imaging (ICMI) lab of the University Brussels (VUB), multiple small animal imaging modalities are centralized together with a unit for probe development and a vivarium for the housing of animals. Different research teams collaborate in an interdisciplinary research effort which encompasses the development and validation of innovative core technologies, their applications in preclinical translational research and the introduction of these emerging technologies into clinical diagnostic imaging practice.  For more information see www.icmibrussels.be.

 About MILabs

MILabs provides high-end molecular imaging solutions for biomedical and pharmaceutical research. Today these systems contribute worldwide to the development of new diagnostic solutions and therapies for diseases such as diabetes, cancer, cardiac and neurodegenerative diseases. U-SPECT4 provides the fastest, most sensitive and highest resolution small-animal SPECT currently available. Recently MILabs introduced VECTor4 and VECTor4CT providing extremely user friendly, fully integrated and simultaneous ultra-high resolution PET/SPECT with a choice of different low-dose high-resolution CT subsystems. For more information see www.milabs.com.

Share on social media

Beckman Institute welcomes new ultra-high-performance PET-CT scanner

Beckman Institute at the University of Illinois, Urbana-Champaign Improves Previous Imaging Functionality with Launch of ...
Read More →

Spotlight on the Orthopedic Imaging at UMC Utrecht, the Netherlands – Prof. Harrie Weinans & Dr. Bart van der Wal

  – Spotlight on the Orthopedic Imaging at UMC Utrecht, the Netherlands –  – Prof. ...
Read More →

Press Release: MILABS launches its 7th generation of preclinical imagers at the World Molecular Imaging Conference 2021

Under the new ownership of the Rigaku Group (Tokyo, Japan), MILabs is pushing the value ...
Read More →

Press Release: RIGAKU Acquires Life Science Imaging Equipment Manufacturer MILabs

August 3, 2021 – Houten, the Netherlands Dear readers, We are very excited that MILabs ...
Read More →

Press Release: Confocal PET Causes Spectral PET Breakthrough in Preclinical Imaging

Houten, the Netherlands – March 24, 2021 Using its unique Confocal PET technology, MILabs B.V ...
Read More →

Spotlight on Akiva Mintz, MD, Ph.D. – Columbia University

Spotlight on Akiva Mintz, MD, Ph.D. – Columbia University – Bridging the “valley of death” ...
Read More →

Spotlight on Bart Cornelissen, PhD – Department of Oncology, Oxford Institute for Radiation Oncology at University of Oxford

– Targeting Tumors from the inside –   Dr. Bart Cornelissen is Group Leader and ...
Read More →

Spotlight on Prof. Twan Lammers – ExMI-RWTH Aachen

A Pioneering Mind in Nanomedicine and Theranostics Prof. Dr. Dr. Twan Lammers is Head of ...
Read More →

Miltenyi Biotec strengthens its research capabilities for cell analysis and preclinical imaging by acquiring a MILabs’ premium Optical/CT imaging system

  Utrecht and Bergisch Gladbach, September 9, 2020 Miltenyi Biotec B.V. & Co. KG, a ...
Read More →

MILabs announced the co-winners of the 2020 MILabs Image of the Year Award

September 4, 2020, Utrecht, The Netherlands Each year, at the occasion of the Annual Congress ...
Read More →

Bayer AS installs top-of-the-line MILabs VECTor PET/SPECT/CT to advance its targeted alpha therapy programs

August 27, 2020, Oslo-Norway and Utrecht-The Netherlands Bayer AS has installed a state-of-the-art MILabs VECTor ...
Read More →

Spotlight on Prof. Marion de Jong – Erasmus MC Rotterdam

Spotlight on Prof. Marion de Jong – Erasmus MC Rotterdam On the frontline of fighting ...
Read More →
Scroll to Top